Erkin Bilalov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Erkin Bilalov has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Asilbek Dauletbaev
Department of Chemistry and Biology, Kimyo International University, Tashkent, Uzbekistan
1 shared publication - Atta Ullah Khan
Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, Italy
1 shared publication - Barno Matchanova
Department of national idea and philosophy, Urgench state pedagogical institute, Urgench, Uzbekistan
1 shared publication - Intizor Avazmetova
Department of Biology, Urgench State University, Urgench, Uzbekistan
1 shared publication - Muhammad Ibrahim
Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, 80138 Naples, Italy
1 shared publication - Mukhayya Ruzieva
Department of Sport and Psychology, Mamun University, Khiva, Uzbekistan
1 shared publication
Latest Publications
- 27 December 2025
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 28 (6) , 2086-2098
Prognostic value of postoperative circulating tumor DNA for recurrence-free survival in resected non-small cell lung cancer: a systematic review and meta-analysis
Background Circulating tumor DNA (ctDNA) has emerged as a promising biomarker for minimal residual disease (MRD) detection in resected non-small cell lung cancer (NSCLC), offering potential for risk stratification and treatment optimization in the postoperative setting. Objective To conduct a systematic review and meta-analysis evaluating the prognostic value of postoperative ctDNA detection for recurrence-free survival and overall survival in patients with surgically resected NSCLC. Methods We systematically searched multiple databases including PubMed, Embase, Web of Science, Scopus, and Cochrane Library, identifying 1,640 initial records. After screening and eligibility assessment, 13 studies encompassing 1,309 patients were included in the quantitative synthesis. Results Immediate postoperative ctDNA detection (4 studies, n = 556) demonstrated a hazard ratio of 6.41 (95% CI: 4.18–9.83, P < 0.00001, I2 = 0%) for recurrence-free survival. MRD assessment (9 studies, n = 1,107) yielded HR = 5.48 (95% CI: 3.71–8.10, P < 0.00001, I2 = 38%). Longitudinal ctDNA monitoring (8 studies, n = 1,102) showed the strongest association with HR = 8.70 (95% CI: 6.03–12.54, P < 0.00001, I2 = 21%). Post-adjuvant chemotherapy ctDNA positivity (3 studies, n = 460) resulted in HR = 2.85 (95% CI: 1.56–5.21, P = 0.0006, I2 = 0%). Overall survival analysis (5 studies) demonstrated HR = 4.47 (95% CI: 2.66–7.52, P < 0.00001, I2 = 0%). Conclusions Postoperative ctDNA detection independently predicts prognosis in resected NSCLC, consistently indicating recurrence risk and guiding adjuvant therapy decisions.
- 27 December 2025
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 28 (6) , 2086-2098
Prognostic value of postoperative circulating tumor DNA for recurrence-free survival in resected non-small cell lung cancer: a systematic review and meta-analysis
Background Circulating tumor DNA (ctDNA) has emerged as a promising biomarker for minimal residual disease (MRD) detection in resected non-small cell lung cancer (NSCLC), offering potential for risk stratification and treatment optimization in the postoperative setting. Objective To conduct a systematic review and meta-analysis evaluating the prognostic value of postoperative ctDNA detection for recurrence-free survival and overall survival in patients with surgically resected NSCLC. Methods We systematically searched multiple databases including PubMed, Embase, Web of Science, Scopus, and Cochrane Library, identifying 1,640 initial records. After screening and eligibility assessment, 13 studies encompassing 1,309 patients were included in the quantitative synthesis. Results Immediate postoperative ctDNA detection (4 studies, n = 556) demonstrated a hazard ratio of 6.41 (95% CI: 4.18–9.83, P < 0.00001, I2 = 0%) for recurrence-free survival. MRD assessment (9 studies, n = 1,107) yielded HR = 5.48 (95% CI: 3.71–8.10, P < 0.00001, I2 = 38%). Longitudinal ctDNA monitoring (8 studies, n = 1,102) showed the strongest association with HR = 8.70 (95% CI: 6.03–12.54, P < 0.00001, I2 = 21%). Post-adjuvant chemotherapy ctDNA positivity (3 studies, n = 460) resulted in HR = 2.85 (95% CI: 1.56–5.21, P = 0.0006, I2 = 0%). Overall survival analysis (5 studies) demonstrated HR = 4.47 (95% CI: 2.66–7.52, P < 0.00001, I2 = 0%). Conclusions Postoperative ctDNA detection independently predicts prognosis in resected NSCLC, consistently indicating recurrence risk and guiding adjuvant therapy decisions.